ACHN Insider Trading Activity and SEC Form 4 Filings
ACHN insider trading summary
No open-market insider purchases or sales of Achillion Pharmaceuticals Inc (ACHN) have been reported on SEC Form 4 in the past 12 months.
Latest ACHN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 13, 2019 | David Scheer | Insider | Sell | $66K (10,485 @ $6.31) |
| Oct 16, 2019 | Joseph Truitt | Chief Executive Officer | Sell | $639K (100,234 @ $6.37) |
| Oct 16, 2019 | Joseph Truitt | Chief Executive Officer | Sell | $212K (33,250 @ $6.37) |
| Nov 20, 2017 | Johnson & Johnson Innovation - JJDC, Inc. | 10% Owner | Sell | $50.5M (18,367,346 @ $2.75) |
| Nov 20, 2017 | & Johnson Johnson | 10% Owner | Sell | $50.5M (18,367,346 @ $2.75) |
| Dec 22, 2016 | Jason S Fisherman | Director | Buy | $40K (10,000 @ $3.96) |
| Dec 5, 2016 | Mary Kay Fenton | Chief Financial Officer | Buy | $10K (2,500 @ $4.11) |
| Dec 2, 2016 | Joseph Truitt | Chief Commercial Officer | Buy | $14K (3,500 @ $4.06) |
| Dec 2, 2016 | Joel C Barrish | Chief Scientific Officer | Buy | $10K (2,500 @ $4.06) |
| Dec 2, 2016 | Martha E Manning | EVP, General Counsel | Buy | $10K (2,500 @ $4.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.